Altered Brain Metabolome Is Associated with Memory Impairment in the rTg4510 Mouse Model of Tauopathy.
Mireia TondoBrandi WasekJoan Carles Escolà-GilDavid de Gonzalo-CalvoClinton HarmonErland ArningTeodoro BottiglieriPublished in: Metabolites (2020)
Alzheimer's disease (AD) is characterized, amongst other features, by the pathologic accumulation of abnormally phosphorylated tau filaments in neurons that lead to neurofibrillary tangles. However, the molecular mechanisms by which the abnormal processing of tau leads to neurodegeneration and cognitive impairment remain unknown. Metabolomic techniques can comprehensively assess disturbances in metabolic pathways that reflect changes downstream from genomic, transcriptomic and proteomic systems. In the present study, we undertook a targeted metabolomic approach to determine a total of 187 prenominated metabolites in brain cortex tissue from wild type and rTg4510 animals (a mice model of tauopathy), in order to establish the association of metabolic pathways with cognitive impairment. This targeted metabolomic approach revealed significant differences in metabolite concentrations of transgenic mice. Brain glutamine, serotonin and sphingomyelin C18:0 were found to be predictors of memory impairment. These findings provide informative data for future research on AD, since some of them agree with pathological alterations observed in diseased humans.
Keyphrases
- cognitive impairment
- wild type
- resting state
- functional connectivity
- white matter
- mouse model
- single cell
- working memory
- cancer therapy
- cerebral ischemia
- cerebrospinal fluid
- ms ms
- spinal cord
- gene expression
- big data
- multiple sclerosis
- neoadjuvant chemotherapy
- artificial intelligence
- high fat diet induced
- cognitive decline
- squamous cell carcinoma
- adipose tissue
- deep learning
- rna seq
- insulin resistance
- radiation therapy
- genome wide